nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ADRB2—prostate cancer	0.407	1	CbGaD
Nadolol—ABCB1—Estramustine—prostate cancer	0.0643	0.2	CbGbCtD
Nadolol—ABCB1—Cabazitaxel—prostate cancer	0.0424	0.132	CbGbCtD
Nadolol—ABCB1—Estrone—prostate cancer	0.0414	0.129	CbGbCtD
Nadolol—ABCB1—Ethinyl Estradiol—prostate cancer	0.0369	0.115	CbGbCtD
Nadolol—ABCB1—Conjugated Estrogens—prostate cancer	0.0271	0.0843	CbGbCtD
Nadolol—ABCB1—Mitoxantrone—prostate cancer	0.0246	0.0767	CbGbCtD
Nadolol—ABCB1—Estradiol—prostate cancer	0.0238	0.074	CbGbCtD
Nadolol—ABCB1—Prednisone—prostate cancer	0.0205	0.0637	CbGbCtD
Nadolol—ABCB1—Etoposide—prostate cancer	0.0155	0.0483	CbGbCtD
Nadolol—ABCB1—Docetaxel—prostate cancer	0.0142	0.0442	CbGbCtD
Nadolol—ABCB1—Doxorubicin—prostate cancer	0.0106	0.033	CbGbCtD
Nadolol—Pirbuterol—ADRB2—prostate cancer	0.000841	0.191	CrCbGaD
Nadolol—Levobunolol—ADRB2—prostate cancer	0.00075	0.17	CrCbGaD
Nadolol—Carteolol—ADRB2—prostate cancer	0.000638	0.144	CrCbGaD
Nadolol—Bupranolol—ADRB2—prostate cancer	0.000542	0.123	CrCbGaD
Nadolol—Salbutamol—ADRB2—prostate cancer	0.00051	0.116	CrCbGaD
Nadolol—Penbutolol—ADRB2—prostate cancer	0.000496	0.112	CrCbGaD
Nadolol—Pindolol—ADRB2—prostate cancer	0.000357	0.081	CrCbGaD
Nadolol—Salbutamol—CYP3A4—prostate cancer	0.000279	0.0632	CrCbGaD
Nadolol—Paraesthesia—Estradiol—prostate cancer	0.000151	0.000708	CcSEcCtD
Nadolol—Asthenia—Conjugated Estrogens—prostate cancer	0.000151	0.000707	CcSEcCtD
Nadolol—Bradycardia—Capecitabine—prostate cancer	0.000151	0.000705	CcSEcCtD
Nadolol—Pruritus—Goserelin—prostate cancer	0.00015	0.000704	CcSEcCtD
Nadolol—Dyspnoea—Estradiol—prostate cancer	0.00015	0.000703	CcSEcCtD
Nadolol—Weight increased—Prednisone—prostate cancer	0.00015	0.000701	CcSEcCtD
Nadolol—Anorexia—Mitoxantrone—prostate cancer	0.00015	0.000701	CcSEcCtD
Nadolol—Pruritus—Conjugated Estrogens—prostate cancer	0.000149	0.000697	CcSEcCtD
Nadolol—Diplopia—Epirubicin—prostate cancer	0.000149	0.000697	CcSEcCtD
Nadolol—Dyspepsia—Estradiol—prostate cancer	0.000148	0.000695	CcSEcCtD
Nadolol—Visual impairment—Docetaxel—prostate cancer	0.000147	0.000689	CcSEcCtD
Nadolol—Hypotension—Mitoxantrone—prostate cancer	0.000147	0.000687	CcSEcCtD
Nadolol—Affect lability—Epirubicin—prostate cancer	0.000147	0.000686	CcSEcCtD
Nadolol—Decreased appetite—Estradiol—prostate cancer	0.000146	0.000686	CcSEcCtD
Nadolol—Depression—Prednisone—prostate cancer	0.000146	0.000685	CcSEcCtD
Nadolol—Diarrhoea—Goserelin—prostate cancer	0.000145	0.000681	CcSEcCtD
Nadolol—Fatigue—Estradiol—prostate cancer	0.000145	0.00068	CcSEcCtD
Nadolol—Constipation—Estradiol—prostate cancer	0.000144	0.000675	CcSEcCtD
Nadolol—Pain—Estradiol—prostate cancer	0.000144	0.000675	CcSEcCtD
Nadolol—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000144	0.000675	CcSEcCtD
Nadolol—Visual impairment—Capecitabine—prostate cancer	0.000142	0.000667	CcSEcCtD
Nadolol—Cardiac failure—Doxorubicin—prostate cancer	0.000141	0.000661	CcSEcCtD
Nadolol—Mood swings—Epirubicin—prostate cancer	0.000141	0.000661	CcSEcCtD
Nadolol—Paraesthesia—Mitoxantrone—prostate cancer	0.000141	0.00066	CcSEcCtD
Nadolol—Loss of consciousness—Etoposide—prostate cancer	0.000141	0.000659	CcSEcCtD
Nadolol—Lethargy—Doxorubicin—prostate cancer	0.000141	0.000659	CcSEcCtD
Nadolol—Dizziness—Goserelin—prostate cancer	0.00014	0.000658	CcSEcCtD
Nadolol—Dyspnoea—Mitoxantrone—prostate cancer	0.00014	0.000655	CcSEcCtD
Nadolol—Cough—Etoposide—prostate cancer	0.00014	0.000654	CcSEcCtD
Nadolol—Dizziness—Conjugated Estrogens—prostate cancer	0.000139	0.000652	CcSEcCtD
Nadolol—Dyspepsia—Mitoxantrone—prostate cancer	0.000138	0.000647	CcSEcCtD
Nadolol—Hypertension—Etoposide—prostate cancer	0.000138	0.000647	CcSEcCtD
Nadolol—Tinnitus—Capecitabine—prostate cancer	0.000138	0.000646	CcSEcCtD
Nadolol—Diplopia—Doxorubicin—prostate cancer	0.000138	0.000645	CcSEcCtD
Nadolol—Dry skin—Epirubicin—prostate cancer	0.000136	0.000639	CcSEcCtD
Nadolol—Decreased appetite—Mitoxantrone—prostate cancer	0.000136	0.000639	CcSEcCtD
Nadolol—Chest pain—Etoposide—prostate cancer	0.000136	0.000638	CcSEcCtD
Nadolol—Affect lability—Doxorubicin—prostate cancer	0.000136	0.000635	CcSEcCtD
Nadolol—Fatigue—Mitoxantrone—prostate cancer	0.000135	0.000634	CcSEcCtD
Nadolol—Vomiting—Goserelin—prostate cancer	0.000135	0.000633	CcSEcCtD
Nadolol—Alopecia—Docetaxel—prostate cancer	0.000135	0.000632	CcSEcCtD
Nadolol—Pain—Mitoxantrone—prostate cancer	0.000134	0.000629	CcSEcCtD
Nadolol—Constipation—Mitoxantrone—prostate cancer	0.000134	0.000629	CcSEcCtD
Nadolol—Bradycardia—Prednisone—prostate cancer	0.000134	0.000628	CcSEcCtD
Nadolol—Rash—Goserelin—prostate cancer	0.000134	0.000628	CcSEcCtD
Nadolol—Dermatitis—Goserelin—prostate cancer	0.000134	0.000627	CcSEcCtD
Nadolol—Vomiting—Conjugated Estrogens—prostate cancer	0.000134	0.000627	CcSEcCtD
Nadolol—Body temperature increased—Estradiol—prostate cancer	0.000133	0.000624	CcSEcCtD
Nadolol—Rash—Conjugated Estrogens—prostate cancer	0.000133	0.000622	CcSEcCtD
Nadolol—Dermatitis—Conjugated Estrogens—prostate cancer	0.000133	0.000621	CcSEcCtD
Nadolol—Gastritis—Epirubicin—prostate cancer	0.000132	0.000617	CcSEcCtD
Nadolol—Hallucination—Prednisone—prostate cancer	0.000131	0.000614	CcSEcCtD
Nadolol—Alopecia—Capecitabine—prostate cancer	0.000131	0.000612	CcSEcCtD
Nadolol—Mood swings—Doxorubicin—prostate cancer	0.000131	0.000611	CcSEcCtD
Nadolol—Abdominal distension—Epirubicin—prostate cancer	0.00013	0.000607	CcSEcCtD
Nadolol—Flatulence—Capecitabine—prostate cancer	0.000127	0.000594	CcSEcCtD
Nadolol—Dry skin—Doxorubicin—prostate cancer	0.000126	0.000591	CcSEcCtD
Nadolol—Nausea—Goserelin—prostate cancer	0.000126	0.000591	CcSEcCtD
Nadolol—Hyperhidrosis—Etoposide—prostate cancer	0.000126	0.000591	CcSEcCtD
Nadolol—Nausea—Conjugated Estrogens—prostate cancer	0.000125	0.000586	CcSEcCtD
Nadolol—Anorexia—Etoposide—prostate cancer	0.000124	0.000583	CcSEcCtD
Nadolol—Body temperature increased—Mitoxantrone—prostate cancer	0.000124	0.000581	CcSEcCtD
Nadolol—Hypotension—Etoposide—prostate cancer	0.000122	0.000571	CcSEcCtD
Nadolol—Gastritis—Doxorubicin—prostate cancer	0.000122	0.000571	CcSEcCtD
Nadolol—Vision blurred—Capecitabine—prostate cancer	0.000121	0.000568	CcSEcCtD
Nadolol—Asthenia—Estradiol—prostate cancer	0.000121	0.000566	CcSEcCtD
Nadolol—Abdominal distension—Doxorubicin—prostate cancer	0.00012	0.000561	CcSEcCtD
Nadolol—Syncope—Docetaxel—prostate cancer	0.000119	0.000558	CcSEcCtD
Nadolol—Pruritus—Estradiol—prostate cancer	0.000119	0.000558	CcSEcCtD
Nadolol—Paraesthesia—Etoposide—prostate cancer	0.000117	0.000549	CcSEcCtD
Nadolol—Weight increased—Epirubicin—prostate cancer	0.000117	0.000549	CcSEcCtD
Nadolol—Loss of consciousness—Docetaxel—prostate cancer	0.000117	0.000547	CcSEcCtD
Nadolol—Dyspnoea—Etoposide—prostate cancer	0.000116	0.000545	CcSEcCtD
Nadolol—Alopecia—Prednisone—prostate cancer	0.000116	0.000545	CcSEcCtD
Nadolol—Cough—Docetaxel—prostate cancer	0.000116	0.000543	CcSEcCtD
Nadolol—Syncope—Capecitabine—prostate cancer	0.000115	0.000541	CcSEcCtD
Nadolol—Diarrhoea—Estradiol—prostate cancer	0.000115	0.00054	CcSEcCtD
Nadolol—Hypertension—Docetaxel—prostate cancer	0.000115	0.000538	CcSEcCtD
Nadolol—Decreased appetite—Etoposide—prostate cancer	0.000113	0.000532	CcSEcCtD
Nadolol—Chest pain—Docetaxel—prostate cancer	0.000113	0.00053	CcSEcCtD
Nadolol—Loss of consciousness—Capecitabine—prostate cancer	0.000113	0.00053	CcSEcCtD
Nadolol—Asthenia—Mitoxantrone—prostate cancer	0.000113	0.000527	CcSEcCtD
Nadolol—Fatigue—Etoposide—prostate cancer	0.000113	0.000527	CcSEcCtD
Nadolol—Cough—Capecitabine—prostate cancer	0.000112	0.000526	CcSEcCtD
Nadolol—Constipation—Etoposide—prostate cancer	0.000112	0.000523	CcSEcCtD
Nadolol—Pain—Etoposide—prostate cancer	0.000112	0.000523	CcSEcCtD
Nadolol—Conjunctivitis—Epirubicin—prostate cancer	0.000112	0.000522	CcSEcCtD
Nadolol—Dizziness—Estradiol—prostate cancer	0.000111	0.000522	CcSEcCtD
Nadolol—Hypertension—Capecitabine—prostate cancer	0.000111	0.00052	CcSEcCtD
Nadolol—Dry mouth—Docetaxel—prostate cancer	0.000111	0.000518	CcSEcCtD
Nadolol—Sweating—Epirubicin—prostate cancer	0.00011	0.000515	CcSEcCtD
Nadolol—Chest pain—Capecitabine—prostate cancer	0.00011	0.000513	CcSEcCtD
Nadolol—Oedema—Docetaxel—prostate cancer	0.000108	0.000508	CcSEcCtD
Nadolol—Weight increased—Doxorubicin—prostate cancer	0.000108	0.000508	CcSEcCtD
Nadolol—Vision blurred—Prednisone—prostate cancer	0.000108	0.000506	CcSEcCtD
Nadolol—Diarrhoea—Mitoxantrone—prostate cancer	0.000107	0.000503	CcSEcCtD
Nadolol—Dry mouth—Capecitabine—prostate cancer	0.000107	0.000502	CcSEcCtD
Nadolol—Vomiting—Estradiol—prostate cancer	0.000107	0.000502	CcSEcCtD
Nadolol—Agranulocytosis—Epirubicin—prostate cancer	0.000107	0.000502	CcSEcCtD
Nadolol—Shock—Docetaxel—prostate cancer	0.000107	0.0005	CcSEcCtD
Nadolol—Rash—Estradiol—prostate cancer	0.000106	0.000497	CcSEcCtD
Nadolol—Dermatitis—Estradiol—prostate cancer	0.000106	0.000497	CcSEcCtD
Nadolol—Oedema—Capecitabine—prostate cancer	0.000105	0.000492	CcSEcCtD
Nadolol—Bradycardia—Epirubicin—prostate cancer	0.000105	0.000491	CcSEcCtD
Nadolol—Anorexia—Docetaxel—prostate cancer	0.000103	0.000484	CcSEcCtD
Nadolol—Shock—Capecitabine—prostate cancer	0.000103	0.000484	CcSEcCtD
Nadolol—Body temperature increased—Etoposide—prostate cancer	0.000103	0.000483	CcSEcCtD
Nadolol—Conjunctivitis—Doxorubicin—prostate cancer	0.000103	0.000483	CcSEcCtD
Nadolol—Syncope—Prednisone—prostate cancer	0.000103	0.000482	CcSEcCtD
Nadolol—Sweating—Doxorubicin—prostate cancer	0.000102	0.000477	CcSEcCtD
Nadolol—Hyperhidrosis—Capecitabine—prostate cancer	0.000102	0.000476	CcSEcCtD
Nadolol—Hypotension—Docetaxel—prostate cancer	0.000101	0.000475	CcSEcCtD
Nadolol—Loss of consciousness—Prednisone—prostate cancer	0.000101	0.000472	CcSEcCtD
Nadolol—Anorexia—Capecitabine—prostate cancer	0.0001	0.000469	CcSEcCtD
Nadolol—Nausea—Estradiol—prostate cancer	0.0001	0.000469	CcSEcCtD
Nadolol—Vomiting—Mitoxantrone—prostate cancer	9.98e-05	0.000467	CcSEcCtD
Nadolol—Visual impairment—Epirubicin—prostate cancer	9.93e-05	0.000465	CcSEcCtD
Nadolol—Agranulocytosis—Doxorubicin—prostate cancer	9.91e-05	0.000464	CcSEcCtD
Nadolol—Hypertension—Prednisone—prostate cancer	9.9e-05	0.000464	CcSEcCtD
Nadolol—Rash—Mitoxantrone—prostate cancer	9.9e-05	0.000464	CcSEcCtD
Nadolol—Dermatitis—Mitoxantrone—prostate cancer	9.89e-05	0.000463	CcSEcCtD
Nadolol—Hypotension—Capecitabine—prostate cancer	9.81e-05	0.00046	CcSEcCtD
Nadolol—Insomnia—Docetaxel—prostate cancer	9.81e-05	0.00046	CcSEcCtD
Nadolol—Paraesthesia—Docetaxel—prostate cancer	9.74e-05	0.000456	CcSEcCtD
Nadolol—Bradycardia—Doxorubicin—prostate cancer	9.7e-05	0.000454	CcSEcCtD
Nadolol—Dyspnoea—Docetaxel—prostate cancer	9.67e-05	0.000453	CcSEcCtD
Nadolol—Tinnitus—Epirubicin—prostate cancer	9.6e-05	0.00045	CcSEcCtD
Nadolol—Dyspepsia—Docetaxel—prostate cancer	9.55e-05	0.000447	CcSEcCtD
Nadolol—Insomnia—Capecitabine—prostate cancer	9.5e-05	0.000445	CcSEcCtD
Nadolol—Paraesthesia—Capecitabine—prostate cancer	9.43e-05	0.000442	CcSEcCtD
Nadolol—Decreased appetite—Docetaxel—prostate cancer	9.43e-05	0.000442	CcSEcCtD
Nadolol—Asthenia—Etoposide—prostate cancer	9.37e-05	0.000439	CcSEcCtD
Nadolol—Dyspnoea—Capecitabine—prostate cancer	9.36e-05	0.000439	CcSEcCtD
Nadolol—Oedema—Prednisone—prostate cancer	9.36e-05	0.000438	CcSEcCtD
Nadolol—Fatigue—Docetaxel—prostate cancer	9.35e-05	0.000438	CcSEcCtD
Nadolol—Nausea—Mitoxantrone—prostate cancer	9.32e-05	0.000437	CcSEcCtD
Nadolol—Pain—Docetaxel—prostate cancer	9.28e-05	0.000435	CcSEcCtD
Nadolol—Constipation—Docetaxel—prostate cancer	9.28e-05	0.000435	CcSEcCtD
Nadolol—Dyspepsia—Capecitabine—prostate cancer	9.25e-05	0.000433	CcSEcCtD
Nadolol—Pruritus—Etoposide—prostate cancer	9.24e-05	0.000433	CcSEcCtD
Nadolol—Shock—Prednisone—prostate cancer	9.2e-05	0.000431	CcSEcCtD
Nadolol—Visual impairment—Doxorubicin—prostate cancer	9.18e-05	0.00043	CcSEcCtD
Nadolol—Decreased appetite—Capecitabine—prostate cancer	9.13e-05	0.000428	CcSEcCtD
Nadolol—Alopecia—Epirubicin—prostate cancer	9.1e-05	0.000426	CcSEcCtD
Nadolol—Fatigue—Capecitabine—prostate cancer	9.06e-05	0.000424	CcSEcCtD
Nadolol—Hyperhidrosis—Prednisone—prostate cancer	9.04e-05	0.000424	CcSEcCtD
Nadolol—Constipation—Capecitabine—prostate cancer	8.98e-05	0.000421	CcSEcCtD
Nadolol—Pain—Capecitabine—prostate cancer	8.98e-05	0.000421	CcSEcCtD
Nadolol—Diarrhoea—Etoposide—prostate cancer	8.93e-05	0.000418	CcSEcCtD
Nadolol—Anorexia—Prednisone—prostate cancer	8.92e-05	0.000418	CcSEcCtD
Nadolol—Tinnitus—Doxorubicin—prostate cancer	8.89e-05	0.000416	CcSEcCtD
Nadolol—Flatulence—Epirubicin—prostate cancer	8.83e-05	0.000414	CcSEcCtD
Nadolol—Dizziness—Etoposide—prostate cancer	8.63e-05	0.000404	CcSEcCtD
Nadolol—Body temperature increased—Docetaxel—prostate cancer	8.58e-05	0.000402	CcSEcCtD
Nadolol—Insomnia—Prednisone—prostate cancer	8.46e-05	0.000396	CcSEcCtD
Nadolol—Vision blurred—Epirubicin—prostate cancer	8.45e-05	0.000396	CcSEcCtD
Nadolol—Alopecia—Doxorubicin—prostate cancer	8.42e-05	0.000394	CcSEcCtD
Nadolol—Paraesthesia—Prednisone—prostate cancer	8.4e-05	0.000394	CcSEcCtD
Nadolol—Body temperature increased—Capecitabine—prostate cancer	8.3e-05	0.000389	CcSEcCtD
Nadolol—Vomiting—Etoposide—prostate cancer	8.3e-05	0.000389	CcSEcCtD
Nadolol—Dyspepsia—Prednisone—prostate cancer	8.24e-05	0.000386	CcSEcCtD
Nadolol—Rash—Etoposide—prostate cancer	8.23e-05	0.000386	CcSEcCtD
Nadolol—Dermatitis—Etoposide—prostate cancer	8.22e-05	0.000385	CcSEcCtD
Nadolol—Flatulence—Doxorubicin—prostate cancer	8.17e-05	0.000383	CcSEcCtD
Nadolol—Decreased appetite—Prednisone—prostate cancer	8.13e-05	0.000381	CcSEcCtD
Nadolol—Fatigue—Prednisone—prostate cancer	8.07e-05	0.000378	CcSEcCtD
Nadolol—Syncope—Epirubicin—prostate cancer	8.04e-05	0.000377	CcSEcCtD
Nadolol—Constipation—Prednisone—prostate cancer	8e-05	0.000375	CcSEcCtD
Nadolol—Loss of consciousness—Epirubicin—prostate cancer	7.88e-05	0.000369	CcSEcCtD
Nadolol—Cough—Epirubicin—prostate cancer	7.82e-05	0.000366	CcSEcCtD
Nadolol—Vision blurred—Doxorubicin—prostate cancer	7.82e-05	0.000366	CcSEcCtD
Nadolol—Asthenia—Docetaxel—prostate cancer	7.78e-05	0.000365	CcSEcCtD
Nadolol—Nausea—Etoposide—prostate cancer	7.75e-05	0.000363	CcSEcCtD
Nadolol—Hypertension—Epirubicin—prostate cancer	7.74e-05	0.000363	CcSEcCtD
Nadolol—Pruritus—Docetaxel—prostate cancer	7.68e-05	0.00036	CcSEcCtD
Nadolol—Chest pain—Epirubicin—prostate cancer	7.63e-05	0.000358	CcSEcCtD
Nadolol—Asthenia—Capecitabine—prostate cancer	7.54e-05	0.000353	CcSEcCtD
Nadolol—Dry mouth—Epirubicin—prostate cancer	7.47e-05	0.00035	CcSEcCtD
Nadolol—Syncope—Doxorubicin—prostate cancer	7.44e-05	0.000348	CcSEcCtD
Nadolol—Pruritus—Capecitabine—prostate cancer	7.43e-05	0.000348	CcSEcCtD
Nadolol—Diarrhoea—Docetaxel—prostate cancer	7.42e-05	0.000348	CcSEcCtD
Nadolol—Body temperature increased—Prednisone—prostate cancer	7.4e-05	0.000346	CcSEcCtD
Nadolol—Oedema—Epirubicin—prostate cancer	7.32e-05	0.000343	CcSEcCtD
Nadolol—Loss of consciousness—Doxorubicin—prostate cancer	7.29e-05	0.000342	CcSEcCtD
Nadolol—Cough—Doxorubicin—prostate cancer	7.24e-05	0.000339	CcSEcCtD
Nadolol—Shock—Epirubicin—prostate cancer	7.2e-05	0.000337	CcSEcCtD
Nadolol—Diarrhoea—Capecitabine—prostate cancer	7.19e-05	0.000337	CcSEcCtD
Nadolol—Dizziness—Docetaxel—prostate cancer	7.17e-05	0.000336	CcSEcCtD
Nadolol—Hypertension—Doxorubicin—prostate cancer	7.16e-05	0.000336	CcSEcCtD
Nadolol—Hyperhidrosis—Epirubicin—prostate cancer	7.07e-05	0.000331	CcSEcCtD
Nadolol—Chest pain—Doxorubicin—prostate cancer	7.06e-05	0.000331	CcSEcCtD
Nadolol—Anorexia—Epirubicin—prostate cancer	6.98e-05	0.000327	CcSEcCtD
Nadolol—Dizziness—Capecitabine—prostate cancer	6.95e-05	0.000325	CcSEcCtD
Nadolol—Dry mouth—Doxorubicin—prostate cancer	6.91e-05	0.000324	CcSEcCtD
Nadolol—Vomiting—Docetaxel—prostate cancer	6.9e-05	0.000323	CcSEcCtD
Nadolol—Rash—Docetaxel—prostate cancer	6.84e-05	0.00032	CcSEcCtD
Nadolol—Hypotension—Epirubicin—prostate cancer	6.84e-05	0.00032	CcSEcCtD
Nadolol—Dermatitis—Docetaxel—prostate cancer	6.83e-05	0.00032	CcSEcCtD
Nadolol—Oedema—Doxorubicin—prostate cancer	6.77e-05	0.000317	CcSEcCtD
Nadolol—Asthenia—Prednisone—prostate cancer	6.71e-05	0.000314	CcSEcCtD
Nadolol—Vomiting—Capecitabine—prostate cancer	6.68e-05	0.000313	CcSEcCtD
Nadolol—Shock—Doxorubicin—prostate cancer	6.66e-05	0.000312	CcSEcCtD
Nadolol—Rash—Capecitabine—prostate cancer	6.62e-05	0.00031	CcSEcCtD
Nadolol—Pruritus—Prednisone—prostate cancer	6.62e-05	0.00031	CcSEcCtD
Nadolol—Insomnia—Epirubicin—prostate cancer	6.62e-05	0.00031	CcSEcCtD
Nadolol—Dermatitis—Capecitabine—prostate cancer	6.62e-05	0.00031	CcSEcCtD
Nadolol—Paraesthesia—Epirubicin—prostate cancer	6.57e-05	0.000308	CcSEcCtD
Nadolol—Hyperhidrosis—Doxorubicin—prostate cancer	6.55e-05	0.000307	CcSEcCtD
Nadolol—Dyspnoea—Epirubicin—prostate cancer	6.52e-05	0.000306	CcSEcCtD
Nadolol—Anorexia—Doxorubicin—prostate cancer	6.45e-05	0.000302	CcSEcCtD
Nadolol—Nausea—Docetaxel—prostate cancer	6.44e-05	0.000302	CcSEcCtD
Nadolol—Dyspepsia—Epirubicin—prostate cancer	6.44e-05	0.000302	CcSEcCtD
Nadolol—Diarrhoea—Prednisone—prostate cancer	6.4e-05	0.0003	CcSEcCtD
Nadolol—Decreased appetite—Epirubicin—prostate cancer	6.36e-05	0.000298	CcSEcCtD
Nadolol—Hypotension—Doxorubicin—prostate cancer	6.33e-05	0.000296	CcSEcCtD
Nadolol—Fatigue—Epirubicin—prostate cancer	6.31e-05	0.000296	CcSEcCtD
Nadolol—Pain—Epirubicin—prostate cancer	6.26e-05	0.000293	CcSEcCtD
Nadolol—Constipation—Epirubicin—prostate cancer	6.26e-05	0.000293	CcSEcCtD
Nadolol—Nausea—Capecitabine—prostate cancer	6.24e-05	0.000292	CcSEcCtD
Nadolol—Dizziness—Prednisone—prostate cancer	6.19e-05	0.00029	CcSEcCtD
Nadolol—Insomnia—Doxorubicin—prostate cancer	6.12e-05	0.000287	CcSEcCtD
Nadolol—Paraesthesia—Doxorubicin—prostate cancer	6.08e-05	0.000285	CcSEcCtD
Nadolol—Dyspnoea—Doxorubicin—prostate cancer	6.04e-05	0.000283	CcSEcCtD
Nadolol—Dyspepsia—Doxorubicin—prostate cancer	5.96e-05	0.000279	CcSEcCtD
Nadolol—Vomiting—Prednisone—prostate cancer	5.95e-05	0.000279	CcSEcCtD
Nadolol—Rash—Prednisone—prostate cancer	5.9e-05	0.000276	CcSEcCtD
Nadolol—Dermatitis—Prednisone—prostate cancer	5.89e-05	0.000276	CcSEcCtD
Nadolol—Decreased appetite—Doxorubicin—prostate cancer	5.89e-05	0.000276	CcSEcCtD
Nadolol—Fatigue—Doxorubicin—prostate cancer	5.84e-05	0.000273	CcSEcCtD
Nadolol—Pain—Doxorubicin—prostate cancer	5.79e-05	0.000271	CcSEcCtD
Nadolol—Constipation—Doxorubicin—prostate cancer	5.79e-05	0.000271	CcSEcCtD
Nadolol—Body temperature increased—Epirubicin—prostate cancer	5.78e-05	0.000271	CcSEcCtD
Nadolol—Nausea—Prednisone—prostate cancer	5.56e-05	0.00026	CcSEcCtD
Nadolol—Body temperature increased—Doxorubicin—prostate cancer	5.35e-05	0.000251	CcSEcCtD
Nadolol—Asthenia—Epirubicin—prostate cancer	5.25e-05	0.000246	CcSEcCtD
Nadolol—Pruritus—Epirubicin—prostate cancer	5.18e-05	0.000243	CcSEcCtD
Nadolol—Diarrhoea—Epirubicin—prostate cancer	5.01e-05	0.000235	CcSEcCtD
Nadolol—Asthenia—Doxorubicin—prostate cancer	4.86e-05	0.000228	CcSEcCtD
Nadolol—Dizziness—Epirubicin—prostate cancer	4.84e-05	0.000227	CcSEcCtD
Nadolol—Pruritus—Doxorubicin—prostate cancer	4.79e-05	0.000224	CcSEcCtD
Nadolol—Vomiting—Epirubicin—prostate cancer	4.65e-05	0.000218	CcSEcCtD
Nadolol—Diarrhoea—Doxorubicin—prostate cancer	4.63e-05	0.000217	CcSEcCtD
Nadolol—Rash—Epirubicin—prostate cancer	4.61e-05	0.000216	CcSEcCtD
Nadolol—Dermatitis—Epirubicin—prostate cancer	4.61e-05	0.000216	CcSEcCtD
Nadolol—Dizziness—Doxorubicin—prostate cancer	4.48e-05	0.00021	CcSEcCtD
Nadolol—Nausea—Epirubicin—prostate cancer	4.35e-05	0.000204	CcSEcCtD
Nadolol—Vomiting—Doxorubicin—prostate cancer	4.3e-05	0.000202	CcSEcCtD
Nadolol—Rash—Doxorubicin—prostate cancer	4.27e-05	0.0002	CcSEcCtD
Nadolol—Dermatitis—Doxorubicin—prostate cancer	4.27e-05	0.0002	CcSEcCtD
Nadolol—Nausea—Doxorubicin—prostate cancer	4.02e-05	0.000188	CcSEcCtD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CD—prostate cancer	1.21e-05	0.000225	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CASP9—prostate cancer	1.21e-05	0.000225	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PLCB2—prostate cancer	1.2e-05	0.000223	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LRP2—prostate cancer	1.2e-05	0.000223	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP2C18—prostate cancer	1.2e-05	0.000223	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PRKCQ—prostate cancer	1.2e-05	0.000223	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NGFR—prostate cancer	1.2e-05	0.000223	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—GSK3B—prostate cancer	1.19e-05	0.000222	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CD—prostate cancer	1.18e-05	0.00022	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAP3K7—prostate cancer	1.18e-05	0.00022	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—INS—prostate cancer	1.18e-05	0.000219	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—P4HB—prostate cancer	1.18e-05	0.000219	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PRKCQ—prostate cancer	1.17e-05	0.000218	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NGFR—prostate cancer	1.17e-05	0.000218	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAP3K7—prostate cancer	1.16e-05	0.000215	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CREBBP—prostate cancer	1.15e-05	0.000215	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	1.15e-05	0.000215	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC22A1—prostate cancer	1.14e-05	0.000213	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—PPARA—prostate cancer	1.14e-05	0.000213	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IGF1—prostate cancer	1.14e-05	0.000212	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGF10—prostate cancer	1.14e-05	0.000212	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—EGFR—prostate cancer	1.13e-05	0.000211	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADRB2—prostate cancer	1.13e-05	0.00021	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SULT2A1—prostate cancer	1.12e-05	0.000208	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	1.11e-05	0.000208	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGF10—prostate cancer	1.11e-05	0.000207	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—JAK2—prostate cancer	1.11e-05	0.000207	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MAP2K1—prostate cancer	1.11e-05	0.000206	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAP2K1—prostate cancer	1.1e-05	0.000205	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CD—prostate cancer	1.1e-05	0.000205	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—VAV3—prostate cancer	1.1e-05	0.000204	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—MED12—prostate cancer	1.1e-05	0.000204	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CD—prostate cancer	1.09e-05	0.000204	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GNG5—prostate cancer	1.09e-05	0.000203	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—JAK2—prostate cancer	1.09e-05	0.000202	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PIK3CA—prostate cancer	1.08e-05	0.000202	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TGFBR2—prostate cancer	1.08e-05	0.000201	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MAP2K1—prostate cancer	1.08e-05	0.000201	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SERPINE1—prostate cancer	1.08e-05	0.000201	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CD—prostate cancer	1.07e-05	0.0002	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—VAV3—prostate cancer	1.07e-05	0.0002	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—KRAS—prostate cancer	1.07e-05	0.000199	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ITPR1—prostate cancer	1.06e-05	0.000198	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TGFBR2—prostate cancer	1.06e-05	0.000197	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CB—prostate cancer	1.05e-05	0.000196	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NCOA3—prostate cancer	1.05e-05	0.000195	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FGF2—prostate cancer	1.05e-05	0.000195	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ITPR1—prostate cancer	1.04e-05	0.000194	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NOS3—prostate cancer	1.03e-05	0.000192	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CB—prostate cancer	1.03e-05	0.000192	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IGF1R—prostate cancer	1.02e-05	0.00019	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCL8—prostate cancer	1.01e-05	0.000189	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—JAK2—prostate cancer	1.01e-05	0.000188	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—JAK2—prostate cancer	1e-05	0.000187	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HPGDS—prostate cancer	1e-05	0.000186	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IGF1R—prostate cancer	9.95e-06	0.000185	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP2C19—prostate cancer	9.94e-06	0.000185	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	9.91e-06	0.000185	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—JAK2—prostate cancer	9.86e-06	0.000184	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PIK3CA—prostate cancer	9.83e-06	0.000183	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MDM2—prostate cancer	9.79e-06	0.000182	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LPL—prostate cancer	9.76e-06	0.000182	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ACHE—prostate cancer	9.7e-06	0.000181	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTT1—prostate cancer	9.7e-06	0.000181	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—IL2—prostate cancer	9.68e-06	0.00018	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PDGFRB—prostate cancer	9.67e-06	0.00018	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ERBB2—prostate cancer	9.65e-06	0.00018	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP2A6—prostate cancer	9.59e-06	0.000179	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CB—prostate cancer	9.57e-06	0.000178	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LPL—prostate cancer	9.54e-06	0.000178	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CB—prostate cancer	9.53e-06	0.000177	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—IL2—prostate cancer	9.47e-06	0.000176	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	9.46e-06	0.000176	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ITGB3—prostate cancer	9.42e-06	0.000175	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	9.41e-06	0.000175	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	9.36e-06	0.000174	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKR1C3—prostate cancer	9.33e-06	0.000174	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PRKACB—prostate cancer	9.28e-06	0.000173	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	9.22e-06	0.000172	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	9.2e-06	0.000171	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP17A1—prostate cancer	9.18e-06	0.000171	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCL8—prostate cancer	9.16e-06	0.000171	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	9.14e-06	0.00017	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	9.13e-06	0.00017	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	9.08e-06	0.000169	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	9e-06	0.000168	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CDKN1B—prostate cancer	8.94e-06	0.000167	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	8.94e-06	0.000167	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	8.93e-06	0.000166	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—AKT1—prostate cancer	8.84e-06	0.000165	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL2—prostate cancer	8.79e-06	0.000164	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CASP3—prostate cancer	8.76e-06	0.000163	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TERT—prostate cancer	8.76e-06	0.000163	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NCOA2—prostate cancer	8.75e-06	0.000163	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL2—prostate cancer	8.75e-06	0.000163	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6—prostate cancer	8.71e-06	0.000162	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL2—prostate cancer	8.6e-06	0.00016	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TERT—prostate cancer	8.57e-06	0.00016	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCND1—prostate cancer	8.53e-06	0.000159	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CTNNB1—prostate cancer	8.45e-06	0.000157	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	8.38e-06	0.000156	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC5A5—prostate cancer	8.35e-06	0.000155	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MMP9—prostate cancer	8.28e-06	0.000154	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CDKN1A—prostate cancer	8.25e-06	0.000154	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PTEN—prostate cancer	8.23e-06	0.000153	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	8.19e-06	0.000153	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LEP—prostate cancer	8.18e-06	0.000152	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP2E1—prostate cancer	8.15e-06	0.000152	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CAV1—prostate cancer	8.1e-06	0.000151	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NQO1—prostate cancer	8.06e-06	0.00015	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—AKT1—prostate cancer	8.03e-06	0.00015	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KDR—prostate cancer	8.01e-06	0.000149	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LEP—prostate cancer	8e-06	0.000149	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TH—prostate cancer	7.95e-06	0.000148	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CAV1—prostate cancer	7.93e-06	0.000148	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP3A4—prostate cancer	7.86e-06	0.000146	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EP300—prostate cancer	7.85e-06	0.000146	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KDR—prostate cancer	7.84e-06	0.000146	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ESR1—prostate cancer	7.81e-06	0.000145	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP1B1—prostate cancer	7.73e-06	0.000144	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ESR1—prostate cancer	7.64e-06	0.000142	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SRC—prostate cancer	7.63e-06	0.000142	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—BAD—prostate cancer	7.62e-06	0.000142	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GGT1—prostate cancer	7.49e-06	0.000139	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—BAD—prostate cancer	7.45e-06	0.000139	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—VEGFA—prostate cancer	7.44e-06	0.000139	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	7.38e-06	0.000137	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APC—prostate cancer	7.38e-06	0.000137	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NCOA1—prostate cancer	7.37e-06	0.000137	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—STAT3—prostate cancer	7.36e-06	0.000137	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EGF—prostate cancer	7.29e-06	0.000136	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IRS1—prostate cancer	7.29e-06	0.000136	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP19A1—prostate cancer	7.27e-06	0.000135	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APC—prostate cancer	7.22e-06	0.000134	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	7.22e-06	0.000134	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EGF—prostate cancer	7.14e-06	0.000133	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IRS1—prostate cancer	7.14e-06	0.000133	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	7.08e-06	0.000132	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—RXRA—prostate cancer	7.01e-06	0.000131	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—INS—prostate cancer	6.99e-06	0.00013	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	6.93e-06	0.000129	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	6.84e-06	0.000127	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MYC—prostate cancer	6.84e-06	0.000127	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—INS—prostate cancer	6.83e-06	0.000127	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TGFB1—prostate cancer	6.83e-06	0.000127	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IGF1—prostate cancer	6.76e-06	0.000126	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—COMT—prostate cancer	6.76e-06	0.000126	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTP1—prostate cancer	6.72e-06	0.000125	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	6.72e-06	0.000125	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	6.69e-06	0.000125	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EGFR—prostate cancer	6.69e-06	0.000125	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ITPR1—prostate cancer	6.62e-06	0.000123	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IGF1—prostate cancer	6.61e-06	0.000123	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	6.58e-06	0.000123	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	6.53e-06	0.000122	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	6.49e-06	0.000121	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	6.43e-06	0.00012	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	6.42e-06	0.00012	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	6.39e-06	0.000119	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	6.35e-06	0.000118	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	6.35e-06	0.000118	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KRAS—prostate cancer	6.32e-06	0.000118	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	6.29e-06	0.000117	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	6.28e-06	0.000117	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TYMS—prostate cancer	6.25e-06	0.000116	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	6.21e-06	0.000116	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGF2—prostate cancer	6.21e-06	0.000116	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTM1—prostate cancer	6.18e-06	0.000115	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOS3—prostate cancer	6.13e-06	0.000114	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGF2—prostate cancer	6.08e-06	0.000113	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—LPL—prostate cancer	6.07e-06	0.000113	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOS3—prostate cancer	5.99e-06	0.000112	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—JAK2—prostate cancer	5.95e-06	0.000111	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP1A1—prostate cancer	5.86e-06	0.000109	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	5.84e-06	0.000109	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—JAK2—prostate cancer	5.82e-06	0.000108	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MDM2—prostate cancer	5.81e-06	0.000108	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ERCC2—prostate cancer	5.81e-06	0.000108	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CA—prostate cancer	5.81e-06	0.000108	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	5.73e-06	0.000107	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	5.71e-06	0.000106	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MDM2—prostate cancer	5.69e-06	0.000106	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	5.65e-06	0.000105	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TP53—prostate cancer	5.62e-06	0.000105	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	5.61e-06	0.000104	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	5.53e-06	0.000103	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—MTHFR—prostate cancer	5.46e-06	0.000102	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	5.43e-06	0.000101	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PPARA—prostate cancer	5.36e-06	9.98e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	5.32e-06	9.9e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	5.31e-06	9.88e-05	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	5.25e-06	9.78e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CASP3—prostate cancer	5.2e-06	9.69e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL2—prostate cancer	5.19e-06	9.67e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	5.19e-06	9.67e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6—prostate cancer	5.17e-06	9.62e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6—prostate cancer	5.14e-06	9.58e-05	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	5.14e-06	9.56e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CASP3—prostate cancer	5.09e-06	9.48e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL2—prostate cancer	5.08e-06	9.46e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCND1—prostate cancer	5.06e-06	9.43e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6—prostate cancer	5.05e-06	9.41e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CAV1—prostate cancer	5.04e-06	9.38e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	5.01e-06	9.34e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCND1—prostate cancer	4.95e-06	9.22e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MMP9—prostate cancer	4.92e-06	9.15e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	4.9e-06	9.13e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	4.9e-06	9.12e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTEN—prostate cancer	4.89e-06	9.1e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MMP9—prostate cancer	4.81e-06	8.96e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	4.79e-06	8.92e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTEN—prostate cancer	4.78e-06	8.9e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	4.77e-06	8.88e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKT1—prostate cancer	4.74e-06	8.84e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	4.66e-06	8.69e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EP300—prostate cancer	4.66e-06	8.68e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CG—prostate cancer	4.59e-06	8.55e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EP300—prostate cancer	4.56e-06	8.49e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SRC—prostate cancer	4.53e-06	8.44e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SRC—prostate cancer	4.43e-06	8.26e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	4.41e-06	8.22e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—STAT3—prostate cancer	4.37e-06	8.14e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—INS—prostate cancer	4.34e-06	8.09e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	4.32e-06	8.04e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STAT3—prostate cancer	4.28e-06	7.96e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CREBBP—prostate cancer	4.25e-06	7.92e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MYC—prostate cancer	4.06e-06	7.56e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	4.05e-06	7.55e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CD—prostate cancer	4.03e-06	7.51e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MYC—prostate cancer	3.97e-06	7.4e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EGFR—prostate cancer	3.97e-06	7.4e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	3.96e-06	7.38e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EGFR—prostate cancer	3.89e-06	7.24e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NOS3—prostate cancer	3.81e-06	7.09e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KRAS—prostate cancer	3.75e-06	6.99e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KRAS—prostate cancer	3.67e-06	6.84e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CB—prostate cancer	3.52e-06	6.55e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTGS2—prostate cancer	3.48e-06	6.49e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	3.45e-06	6.42e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	3.37e-06	6.28e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TP53—prostate cancer	3.33e-06	6.21e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TP53—prostate cancer	3.26e-06	6.08e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6—prostate cancer	3.05e-06	5.69e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTEN—prostate cancer	3.04e-06	5.66e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6—prostate cancer	2.99e-06	5.56e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—EP300—prostate cancer	2.9e-06	5.4e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKT1—prostate cancer	2.82e-06	5.25e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKT1—prostate cancer	2.75e-06	5.13e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CA—prostate cancer	2.14e-06	3.99e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKT1—prostate cancer	1.75e-06	3.26e-05	CbGpPWpGaD
